Hemophilia B gene therapy: a NAb–solute barrier overcome by adeno-associated virus serotype 5

Read full text Summarise with VIRAT
Authors: Radosław Kaczmarek
Cited by: 0
References: 20

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Early preclinical and clinical studies on gene therapy using adeno-associated viral (AAV) vectors established that neutralizing anti-AAV antibodies (NAbs) block transduction, thereby abolishing efficacy. In mice and nonhuman primates, coinjection of AAV8 with immunoglobulins from an anti-AAV8–positive individuals, or pre-existing titers exceeding 1:5, prevented transgene expression [1,2]. Similarly, phase 1/2 clinical trials of gene therapy for hemophilia B showed that anti-AAV2 and anti-AAV8 titers as low as 1:1 to 1:3.8 reduced factor (F)IX expression by 50% to 96% [3,4].

Fields of Study & Subjects

Virus-based gene therapy research Hemophilia Treatment and Research RNA Interference and Gene Delivery

Publication details

Journal / source
Research and Practice in Thrombosis and Haemostasis
Volume
10
Issue
3
Pages
103428–103428
Publication date
1 March 2026
Language
EN